Keyphrases
Immunocompromised Patients
100%
Tyrosine Kinase Inhibitor
100%
Clinical Benefit
100%
Metastatic Merkel Cell Carcinoma
100%
Vascular Endothelial Growth Factor Receptor (VEGFR)
75%
Merkel Cell Carcinoma
50%
Pazopanib
50%
Skin Cancer
25%
Patient Survival
25%
Chemotherapy
25%
Therapeutic Potential
25%
Immunosuppression
25%
Arthritis
25%
5-year Survival
25%
Effective Treatment
25%
Nave
25%
Programmed Death-ligand 1 (PD-L1)
25%
Metastatic Disease
25%
Unmet Needs
25%
High Response Rate
25%
Complete Response
25%
Cytotoxic Chemotherapy
25%
Rare Diseases
25%
Psoriatic Arthritis
25%
Median Progression-free Survival
25%
Vascular Endothelial Growth Factor Receptor Inhibitor
25%
Cabozantinib
25%
Anti-PD-L1 Antibody
25%
Medicine and Dentistry
Tyrosine-Kinase Inhibitor
100%
Merkel Cell Carcinoma
100%
Vasculotropin Receptor
80%
Immunotherapy
60%
Pazopanib
40%
Diseases
40%
Metastatic Carcinoma
20%
Protein Tyrosine Kinase
20%
Immunosuppressive Treatment
20%
Arthritis
20%
Skin Cancer
20%
Cytotoxic Chemotherapy
20%
Progression Free Survival
20%
Rare Disease
20%
Psoriatic Arthritis
20%
Programmed Death-Ligand 1
20%
Cabozantinib
20%
Effective Treatment
20%
Pharmacology, Toxicology and Pharmaceutical Science
Protein Tyrosine Kinase Inhibitor
100%
Merkel Cell Carcinoma
100%
Vasculotropin Receptor
80%
Immunotherapy
60%
Pazopanib
40%
Diseases
40%
Chemotherapy
20%
Arthritis
20%
Protein Tyrosine Kinase
20%
Progression Free Survival
20%
Cytotoxic Chemotherapy
20%
Skin Cancer
20%
Rare Disease
20%
Cabozantinib
20%
Psoriatic Arthritis
20%
Nursing and Health Professions
Merkel Cell Carcinoma
100%
Protein Tyrosine Kinase Inhibitor
100%
Vasculotropin Receptor
80%
Immunotherapy
60%
Diseases
40%
Pazopanib
40%
Arthritis
20%
Immunosuppressive Treatment
20%
Skin Cancer
20%
Psoriatic Arthritis
20%
Progression Free Survival
20%
Rare Disease
20%
Protein Tyrosine Kinase
20%
Cabozantinib
20%